“CE mark certification under the new requirements is a high bar and we are proud of this significant company achievement. Meeting the rigor of the new framework is an important milestone for our AFX2 system,” said Elisa Hebb, Endologix’s EVP of Medical, Clinical, Regulatory Affairs and Quality.
“We believe AFX2 offers an innovative solution for AAA and continues to play a significant role in clinical practice due to its differentiated design features and the compendium of clinical evidence,” said Matt Thompson, president and CEO of Endologix, “We are committed to investing in clinical research to evaluate the long-term outcomes of our products. Evidence to date supports the comparative effectiveness of AFX2 in the treatment of patients with abdominal aneurysms.”
The currently marketed AFX2 system was introduced in 2016 and its comparative performance is studied in the LEOPARD randomised controlled trial. The study was designed to directly compare AFX2 and the predecessor AFX device, to other commercially available endografts.
A company press release advises that the five-year results of this study will be available later this year, while the four-year results demonstrated that freedom from aneurysm related complications was similar between the AFX and AFX2 cohort and comparator endografts.